Related Experiment Video

Updated: May 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer]

Klaus Brasso1, Frederik Birkebæk Thomsen, Kasper Drimer Berg

  • 1Urologisk Klinik, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. klausbrasso@hotmail.com

Ugeskrift for Laeger
|October 2, 2013
PubMed

Insights

Castration-resistant prostate cancer (CRPC) progresses despite low testosterone but still responds to hormonal treatments. New therapies targeting androgen receptor signalling and testosterone synthesis offer improved management options for CRPC patients.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Prostate cancer progression despite low testosterone defines castration-resistant prostate cancer (CRPC).
  • Androgen receptor (AR) signalling remains a key driver in CRPC progression.
  • CRPC remains sensitive to hormonal manipulation.

Purpose of the Study:

  • To review pivotal phase 3 trials of new endocrine treatments for CRPC.
  • To discuss the implications of these new treatments for the future management of CRPC.

Main Methods:

  • Review of pivotal phase 3 clinical trials.
  • Analysis of treatment efficacy and safety data.
  • Discussion of clinical implications.

Main Results:

  • New endocrine treatments, including AR signalling inhibitors and testosterone synthesis inhibitors, have been approved for CRPC.
  • These therapies demonstrate efficacy in managing CRPC progression.
  • Phase 3 trials provide evidence for their role in hormonal manipulation.

Conclusions:

  • CRPC treatment landscape is evolving with new endocrine therapies.
  • Androgen receptor signalling inhibitors and testosterone synthesis inhibitors represent significant advancements.
  • Future CRPC management will likely incorporate these novel hormonal treatments based on pivotal trial data.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...